FREQUENTLY ASKED QUESTIONS
What is the official ID of this bill?
The official print number for this legislation is 117_HR_5388.
Which chamber initiated this legislation?
This legislation was initiated in the House of Representatives.
When did the legislative process begin?
The process officially started on 2021-09-27.
What are the main provisions?
Key points include:
- A public list of essential generic medicines that must always be available will be established.
- A strategic reserve of ingredients for these medicines will be created, prioritizing domestic manufacturers.
- Pharmaceutical companies will find it easier to switch to reserve ingredient sources without unnecessary bureaucracy.
- A plan to boost domestic production of drug ingredients will reduce reliance on imports.
What is the specific legal status?
The current status is Expired.
Where can I read the full text of this legislation?
The full official text is available at:
View full text
Who is the primary sponsor?
The primary sponsor is Rep. Spanberger, Abigail Davis [D-VA-7].
What is the latest detailed status?
The latest detailed status is: Referred to the Subcommittee on Health.
Is this summary verified?
Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.
What is the impact of this bill?
We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.